Evidence map›Paper›PMID 39450547›Full record

ArticleInternational journal of oncology2024

Yusuke Nakano, Takaaki Masuda, Takeharu Sakamoto, Noritaka Tanaka, Taro Tobo, Masahiro Hashimoto, Takanari Tatsumi, Hideyuki Saito, Junichi Takahashi, Kensuke Koike and 15 more

Abstract read
In one paragraph

Article in International journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yusuke NakanoDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Takaaki MasudaDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Takeharu SakamotoDepartment of Cancer Biology, Institute of Biomedical Science, Kansai Medical University, Osaka 573‑1010, Japan.
Noritaka TanakaDepartment of Cancer Biology, Institute of Biomedical Science, Kansai Medical University, Osaka 573‑1010, Japan.
Taro ToboDepartment of Clinical Laboratory Medicine, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Masahiro HashimotoDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Takanari TatsumiDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Hideyuki SaitoDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Junichi TakahashiDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Kensuke KoikeDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Tadashi AbeDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Yuki AndoDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Yuki OzatoDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Kiyotaka HosodaDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Kosuke HiroseDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Satoshi HiguchiDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Tomohiko IkeharaDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Yuichi HisamatsuDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Takeo ToshimaDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Yusuke YonemuraDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.
Takayuki OginoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka 565‑0871, Japan.
Mamoru UemuraDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka 565‑0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka 565‑0871, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka 565‑0871, Japan.
Koshi MimoriDepartment of Surgery, Kyushu University Beppu Hospital, Oita 874‑0838, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is widely prevalent and represents a significant contributor to global cancer‑related mortality. There remains a pressing demand for advancements in CRC treatment modalities. The E3 ubiquitin ligase is a critical enzyme involved in modulating protein expression levels via posttranslational ubiquitin‑mediated proteolysis, and it is reportedly involved in the progression of various cancers, making it a target of recent interest in anticancer therapy. In the present study, using comprehensive expression analysis involving spatial transcriptomic analysis with single‑cell RNA sequencing in clinical CRC datasets, the ubiquitin‑associated protein Shank‑associated RH domain interactor (

Indexed as

Colorectal NeoplasmsGene Expression Regulation, NeoplasticTumor Suppressor Protein p53AnimalsApoptosisCell Line, TumorCell ProliferationFemaleHumansMaleMiceMiddle AgedPrognosisProto-Oncogene Proteins c-mdm2UbiquitinsUp-RegulationMDM2 protein, humanProto-Oncogene Proteins c-mdm2SHARPIN protein, humanTP53 protein, humanTumor Suppressor Protein p53Ubiquitinscolorectal cancernovel genep53shank‑associated RH domain interactorubiquitin‑proteasome system

Identifiers

PMID39450547
PMCPMC11542962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.